Design of freeze-drying processes is often approached with a "trial and error" experimental plan or, worse yet, the protocol used in the first laboratory run is adopted without further attempts at optimization. Consequently, commercial freeze-drying processes are often neither robust nor efficient. It is our thesis that design of an "optimized" freeze-drying process is not particularly difficult for most products, as long as some simple rules based on well-accepted scientific principles are followed. It is the purpose of this review to discuss the scientific foundations of the freeze-drying process design and then to consolidate these principles into a set of guidelines for rational process design and optimization. General advice is given concerning common stability issues with proteins, but unusual and difficult stability issues are beyond the scope of this review. Control of ice nucleation and crystallization during the freezing step is discussed, and the impact of freezing on the rest of the process and final product quality is reviewed. Representative freezing protocols are presented. The significance of the collapse temperature and the thermal transition, denoted Tg', are discussed, and procedures for the selection of the "target product temperature" for primary drying are presented. Furthermore, guidelines are given for selection of the optimal shelf temperature and chamber pressure settings required to achieve the target product temperature without thermal and/or mass transfer overload of the freeze dryer. Finally, guidelines and "rules" for optimization of secondary drying and representative secondary drying protocols are presented.
Increased interest in molecular time scales below the glass transition temperature, T
g, has arisen from the
desire to identify the conditions (e.g., temperature) where the molecular processes which lead to unwanted
changes in amorphous systems (e.g., chemical reactivity, crystallization, structural collapse) are improbable.
The purpose of this study was to characterize the molecular mobility of selected amorphous systems (i.e.,
indomethacin, sorbitol, sucrose, and trehalose) below T
g using a combined experimental and theoretical
approach. Of particular interest was the temperature where the time scales for molecular motion (i.e., relaxation
time) exceed expected lifetimes or storage times. As a first approximation of this temperature, the temperature
where the thermodynamic properties of the crystal and the equilibrium supercooled liquid converge (i.e., the
Kauzmann temperature, T
K) was determined. T
K values derived from heat capacity and enthalpy of fusion
data ranged from 40 to 190 K below the calorimetric T
g. A more refined approach, using a form of the
Vogel−Tamman−Fulcher (VTF) equation derived from the Adam−Gibbs formulation for nonequilibrium
systems below T
g, was used to predict the temperatures where the relaxation times of real glasses exceed
practical storage times. Relaxation times in glasses were characterized in terms of their fictive temperature,
as determined from heat capacity data measured using modulated differential scanning calorimetry. The
calculated relaxation times were in good agreement with measured relaxation times for at least two materials.
Relaxation times in real glasses were on the order of three years at temperatures near T
K, indicating low (but
not zero) mobility under conditions where the equilibrium supercooled liquid experiences total loss of structural
mobility. The results of this study demonstrate the importance of excess configurational entropy formed during
vitrification in determining structural relaxation dynamics in real glasses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.